The impact of trisomy 12, retinoblastoma gene and P53 in prognosis of B-cell chronic lymphocytic leukemia

References

• Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.
   PubMed Web of Science ®Google Scholar
• Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, SiakantarisMP, Kittas C. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Walden-strom's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol 1999; 36: 104–114.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, vardiman J. Pathology and genetic oftumors of haemopoietic and lymphoid tissues, 1st ed. Lyon: IARC Press, 2001.
   Google Scholar
• Keating MJ, Chiorazzi N, Messmer B et al. Biology and treatmentof chronic lymphocytic leukemia. Hematology 2003. American Socoity of Hematology Education Program book Washington, DC: American Society of Hematology, 2003; 153-175.
   Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS: Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206.
   PubMed Web of Science ®Google Scholar
• Zwiebel JA, Cheson BD: Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 1998; 25: 42–59.
   PubMed Web of Science ®Google Scholar
• Aoun P, Blair HE, Smith LM et al. Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 2004; 45: 1595–1603.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
   PubMed Web of Science ®Google Scholar
• Gahrton G, Robert KH, Friberg K, Zech L, Bird AG. Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B-cell-mitogen stimulation. Blood 1980; 56: 640–647.
   PubMed Web of Science ®Google Scholar
• Robert KH, Gahrton G, Friberg K, Zech L, Nilsson B. Extra chromosome 12 and prognosis in chronic lymphocytic leukaemia. Scand J Haematol 1982; 28: 163–168.
   PubMedGoogle Scholar
• Neilson JR, Auer R, White D et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997; 11: 1929–1932.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Oscier D, Fitchett M. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720–724.
   PubMed Web of Science ®Google Scholar
• Dohner h, Stilgenbauer S, Benner A. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993–1007.
   PubMed Web of Science ®Google Scholar
• Moorhead PS, Nowell PC, Mellman WJ, Battips DM, Hungerford DA. Chromosome preparations of leukocytes cultured from human peripheral blood. Exp Cell Res 1960; 20: 613–616.
   PubMed Web of Science ®Google Scholar
• Paris Conference (1971), supplement (1975). Standardization in human cytogenetics. Cytogenet Cell Genet 1975; 15: 203–238.
   PubMedGoogle Scholar
• An International System for Human Cytogenetic Nomenclature (1985) ISCN 1985. Report of the Standing Committee on Human Cytogenetic Nomenclature. Birth Defects Orig Artie Ser 1985; 21: 1–117.
   PubMedGoogle Scholar
• Garcia-Marco JA, Nouel A, Navarro B et al. Molecular cytogenetic analysis in splenic lymphoma with villous lymphocytes: frequent allelic imbalance of the RBI gene but not the D13525 locus on chromosome 13q14. Cancer Res 1998; 58: 1736–1740.
   PubMed Web of Science ®Google Scholar
• Shaw GR, Kronberger DL. TP53 deletions but not trisomy 12 are adverse in B-cell lymphoproliferative disorders. Cancer Genet Cytogenet 2000; 119: 146–154.
   PubMed Web of Science ®Google Scholar
• Dewald GW. Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma. Int J Hematol 2002; 76(Suppl 2): 65–74.
   PubMedGoogle Scholar
• Dewald GW, Brockman SR, Paternoster SF et al. Chromosome anomalies detected by interphase fluorescence in situ hybridiza-tion: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003; 121: 287–295.
   PubMed Web of Science ®Google Scholar
• Oscier DG, Gardiner AC, Mould Si et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177–1184.
   PubMed Web of Science ®Google Scholar
• Jarosova M, Jedlickova K, Holzerova M et al. Methods in molecular cytogenetics for determination of prognostically impor-tant chromosome changes in patients with chronic lymphatic leukemias. Cas Lek Cesk 2000; 139: 564–569.
   PubMedGoogle Scholar
• Byrd JC, Smith L, Hackbarth ML et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003; 63: 36–38.
   PubMed Web of Science ®Google Scholar
• El Rouby S, Thomas A, Costin D et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR I/MDR3 gene expression. Blood 1993; 82: 3452–3459.
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–1589.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Gribben JG, Peterson BL et al. Select high-risk genetic features predict earlier progression following chemoimmunother-apy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437–443.
   PubMed Web of Science ®Google Scholar